CAMBRIDGE, Mass.--(BUSINESS WIRE)--Korro Bio, Inc., an RNA editing company focused on the discovery and development of novel genetic medicines, today announced that Ram Aiyar, Ph.D., MBA, Chief Executive Officer, will participate in two upcoming virtual healthcare investor conferences, as follows:
Evercore ISI 4th Annual HealthCONx Conference
Format: Fireside chat
Date and time: Thursday, December 2, 2021 from 8:50 – 9:10 a.m. ET
Piper Sandler 33rd Annual Virtual Healthcare Conference
Date and time: Pre-recorded presentation accessible for registered attendees via the Piper Sandler conference website starting on Monday, November 22, 2021 at 10:00 a.m. ET
About Korro Bio, Inc.
Korro is an RNA editing company focused on discovery and development of a new class of precision genetic medicines. The synthetic oligonucleotide platform, OPERATM, is a modular drug discovery engine that combines proprietary data-driven design with off-the-shelf chemistry and delivery to achieve highly selective RNA editing. This unique technology enables the functional benefits of gene therapy with a transient, repeated-administration regimen that permits pharmacologic titration of therapeutic efficacy and safety. As a result, Korro’s portfolio of innovative RNA therapies have the potential to propel genetic medicine beyond rare genetic diseases into larger patient populations with common diseases. Korro is located in Cambridge, Mass. For more information, visit korrobio.com.